OSR Holdings Names Dr. Andreas Niethammer of CEO Of Vaximm AG
14 Nov 2025 //
PR NEWSWIRE
Vaximm AG Announces Phase 2a Trial Results for Glioblastoma
26 Mar 2025 //
PR NEWSWIRE
NEC OncoImmunity acquires Vaximm`s neoantigen vaccine development assets
09 Mar 2022 //
PHARMABIZ
NEC, VAXIMM to advance personalized neoantigen cancer vaccines
15 Nov 2019 //
BIOSPECTRUM ASIA

Market Place
Sourcing Support